Text Size

Asthma Control Study 2011

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01298739
First received: February 16, 2011
Last updated: October 24, 2011
Last verified: October 2011
History of Changes
  Purpose

Asthma control study 2011


Condition
Asthma Control Level

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Asthma Control Study 2011

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Asthma control level [ Time Frame: 2 times ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Routine Therapeutical habits in control maintenance [ Time Frame: 2 time ] [ Designated as safety issue: No ]

Enrollment: 1524
Study Start Date: February 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Asthmatic patients above 18 y

Criteria

Inclusion Criteria:

  • Asthmatic patients above 18 y

Exclusion Criteria:

  • COPD
  • pulmonary cancer
  • pulmonary tuberculosis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01298739

  Show 53 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: György Losonczy, MD PHD Semmelweis University Budapest Pulmonology Clinic
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01298739     History of Changes
Other Study ID Numbers: NIS-RHU-XXX-2011/1
Study First Received: February 16, 2011
Last Updated: October 24, 2011
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
asthma control level , ACQ

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013